Form 4: Provectus Biopharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
Edward Pershing, CEO, a Director and 10% owner of Provectus Biopharmaceuticals, Inc., reported multiple transactions in common stock on September 18, 2026.
Summary
- Option exercise/conversion: disposed of 0 8% Unsecured Convertible Promissory Note on September 18, 2026 (Direct).
- Option exercise/conversion: acquired 13,216 Series D-1 Convertible Preferred Stock on September 18, 2026; holds 2,962,709 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Edward Pershing — Director, Officer (CEO), 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Option exercise/conversion | 8% Unsecured Convertible Promissory Note | 0 | — | — | 0 |
| 2026-09-18 | Option exercise/conversion | Series D-1 Convertible Preferred Stock | 13,216 | — | — | 2,962,709 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Option exercise/conversion (0 shares) |
| 2026-09-18 | Option exercise/conversion (13,216 shares) |
Keywords
insider transaction, Form 4, PVCT, PROVECTUS BIOPHARMACEUTICALS, INC., neutral, Edward Pershing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.